Efficacy News and Research

RSS

Potential drug treatment for AXL-low expressing EGFR-mutated lung cancer

Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.

5 Oct 2020

New approach transforms oldest antibiotics into safer, stronger drugs

Physicians and scientists have long searched the natural world for chemicals that can improve human health. However, evolutionary selection optimized natural chemicals to benefit their host, not for safety or efficacy in humans.

5 Oct 2020

Anti-sense agents suppress SARS-CoV-2 virus

Researchers in the United States have conducted a study showing that anti-sense agents called peptide-conjugated morpholino oligomers (PPMOs) have the ability to specifically and potently suppress the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

4 Oct 2020

PATH wins grant to develop oral treatment option for soil-transmitted helminth infections

PATH announced today they received a grant from Japan's Global Health Innovative Technology Fund to develop a new oral treatment option for soil-transmitted helminth infections.

1 Oct 2020

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process.

1 Oct 2020

Researchers identify a promising method to treat multiple sclerosis

Seema Tiwari-Woodruff, a professor of biomedical sciences in the School of Medicine at the University of California, Riverside, and her colleagues have received a grant of $373,000 from the National Multiple Sclerosis Society for a project in which her lab will select the five best candidate compounds to speed up nerve impulses, a promising new avenue to treat multiple sclerosis.

1 Oct 2020

Investigational mRNA vaccine to prevent SARS-CoV-2 shows promise in older adults

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.

30 Sep 2020

NIH awards grants for using bioengineered models to improve clinical trial design

Clinical Trials on a Chip researchers plan to build and test common and rare disease models to help improve the clinical trial process.

30 Sep 2020

A TLR2 agonist reduces SARS-CoV-2 in upper respiratory tract of ferret model

In a recent bioRxiv* preprint paper, Professor Miles W. Carroll et al. study an agonist for reducing the SARS-CoV-2's viral load. They show that prophylactic intra-nasal administration of TLR2/6 (toll-like receptor) agonist, INNA-051, reduces viral RNA in the nose and throat, in a ferret model.

30 Sep 2020

Study shows how Cisplatin chemotherapy leads to neuronal apoptosis

Despite the great advances in cancer research in recent years, treatments that can cause very severe adverse effects are still used. This is the case of neuropathy caused by chemotherapy with platinum derivatives, such as Cisplatin and Oxaliplatin.

30 Sep 2020

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

A new study by researchers at the Indian Institute of Science and the University of Queensland and published on the preprint server medRxiv in September 2020 discusses using a novel tool to identify the most effective among currently known anti-SARS-CoV-2 NAbs.

29 Sep 2020

Nasal calcium-rich salts effectively eliminate airborne particles from airways

In a paper published in Molecular Frontiers Journal, researchers from Cambridge, Massachusetts have discovered a more effective way of eliminating airborne particles from airways using nasal calcium-rich salts called FEND, which have potential applications in the fight against Covid-19.

29 Sep 2020

Dartmouth TB vaccine moves one step closer to a full Phase 3 efficacy trial

Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth's Geisel School of Medicine and published in the journal Vaccine.

29 Sep 2020

Novel immunotherapy platform can connect mussel adhesive proteins to the antibodies

Antibody-based immunotherapy is one of treatment options for cancer immunotherapy by modulating our immune system with therapeutic antibodies.

29 Sep 2020

PrimeStore® MTM novel viral transport media successfully evaluated by Public Health England for SARS-CoV-2 inactivation

EKF Diagnostics announces that the novel viral transport media PrimeStore® MTM has been successfully evaluated for effective SARS-CoV-2 inactivation.

From EKF Diagnostics 29 Sep 2020

Phase 1 trial of new class of drugs shows promise in range of advanced cancers

A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.

29 Sep 2020

New study shows efficacy of carbon nanotube implants to restore motor functions

A new study conducted by SISSA and the University of Trieste shows the efficacy of carbon nanotube implants to restore motor functions and paves the way for a new therapeutic approach for spinal cord injuries.

29 Sep 2020

Mental preparedness of nurses and nursing students in India for COVID-19

Researchers from Bengaluru, India, tried to assess the psychological preparedness of Indian nurses and nursing students in the face of the COVID-19 pandemic. The pandemic that has now affected over 33.27 million people worldwide seems to rage on unabated and is something that these healthcare workers have never faced before in their careers.

28 Sep 2020

Cincinnati Children's research leads to approval of new drug for hypereosinophilic syndrome

Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children's Hospital Medical Center, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.

28 Sep 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

Efficacy News and Research

Potential drug treatment for AXL-low expressing EGFR-mutated lung cancer

New approach transforms oldest antibiotics into safer, stronger drugs

Anti-sense agents suppress SARS-CoV-2 virus

PATH wins grant to develop oral treatment option for soil-transmitted helminth infections

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

Researchers identify a promising method to treat multiple sclerosis

Investigational mRNA vaccine to prevent SARS-CoV-2 shows promise in older adults

NIH awards grants for using bioengineered models to improve clinical trial design

A TLR2 agonist reduces SARS-CoV-2 in upper respiratory tract of ferret model

Study shows how Cisplatin chemotherapy leads to neuronal apoptosis

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

Nasal calcium-rich salts effectively eliminate airborne particles from airways

Dartmouth TB vaccine moves one step closer to a full Phase 3 efficacy trial

Novel immunotherapy platform can connect mussel adhesive proteins to the antibodies

PrimeStore® MTM novel viral transport media successfully evaluated by Public Health England for SARS-CoV-2 inactivation

Phase 1 trial of new class of drugs shows promise in range of advanced cancers

New study shows efficacy of carbon nanotube implants to restore motor functions

Mental preparedness of nurses and nursing students in India for COVID-19

Cincinnati Children's research leads to approval of new drug for hypereosinophilic syndrome

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News